Nimotuzumab
As of the edition of 20 October 2026, Nimotuzumab is an antibody: stopped in 2024; acts on EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 134, 14 stopped early
- Disease areas
- Cancer; Digestive system; Ear, nose and throat; Mouth and teeth; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Nimotuzumab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 3 | 2 | 0 |
| Phase 1 | 7 | 3 | 1 | 1 |
| Phase 2 | 89 | 19 | 25 | 10 |
| Phase 3 | 26 | 6 | 12 | 3 |
| Phase 4 | 3 | 0 | 1 | 0 |
| All trials | 134 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| YM BioSciences | Lead sponsor of trials | 2005 to now |
| Oncoscience | Lead sponsor of trials | 2006 to now |
| Biotech Pharmaceutical | Lead sponsor of trials | 2008 to now |
| Eurofarma Laboratorios | Lead sponsor of trials | 2009 to now |
| Kuhnil Pharmaceutical | Lead sponsor of trials | 2013 to now |
| El Kendi Pharmaceuticals Manufacturing | Lead sponsor of trials | 2015 to now |